Studies showed the painkiller Vioxx had heart side effects years before drugmaker Merck pulled the pill off the market.

Even as drug makers promise to support Washington’s health care overhaul by shaving $8 billion a year off the nation’s drug costs after the legislation takes effect, the industry has been raising its prices at the fastest rate in years, reports the New York Times.

The results of a highly-anticipated head-to-head cholesterol drug study further calls into question the level of effectiveness of Merck's  blockbusters Zetia and Vytorin.

For top analysts from investment banks, including JPMorgan  and Credit Suisse , or some of their minions, the destination is a cardiology conference where on Monday morning medical researchers are expected to present a study with potentially significant implications for multibillion-dollar cholesterol medications from the drug giant Merck.

New York City health officials scrambled to explain themselves Thursday following outraged media reports about bankers who got scarce H1N1 flu vaccines through their employers

A new study says doctors should be especially vigilant about people who are over 50 with flu symptoms because they appear to have a higher risk of death from H1N1.

The director of the FDA's division of antiviral products is urging caution in the use of a new flu drug that just won special permission to fight H1N1.

Dendreon has completed its U.S. regulatory submission for its closely watched experimental prostate cancer vaccine, the company said Monday, sending its shares up 5 percent.

A large study being published in a major medical journal says certain kidney disease patients who get the drug Aranesp to treat anemia-related fatigue may be at greater risk of having a stroke.

Stocks rallied Thursday, rebounding off of the prior session's rout, after reports showed the economy grew more than expected last quarter and jobless claims fell. The Dow jumped more than 2 percent—its best day since July.

Stocks rallied Thursday, rebounding off of the prior session's rout, after reports showed the economy grew more than expected last quarter and jobless claims fell.

Stocks rallied Thursday, rebounding off of the prior session's rout, after reports showed the economy grew more than expected last quarter and jobless claims fell.

Futures pointed to a positive open for Wall Street on Thursday ahead of the all-important U.S. third-quarter gross domestic product data.

Stocks tumbled to session lows late Wednesday, with the Dow down more than 100 points, as worries about the recovery gripped the market.

Stocks were lower at the halfway point Wednesday as investors shrugged off some good news and worries about the recovery gripped the market.